We are live on ! Find out more
TCM

Tamarack Capital Management Portfolio holdings

AUM $840M
1-Year Est. Return 19.47%
This Fund
S&P 500
This Quarter Est. Return
+17.08%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$199M
Cap. Flow
+$168M
Cap. Flow %
44.51%
Top 10 Hldgs %
63.15%
Holding
34
New
10
Increased
13
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$22.4M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$9.03M
3
CFN
CAREFUSION CORPORATION
CFN
+$8.4M
4
EW icon
Edwards Lifesciences
EW
+$7.88M
5
NTUS
Natus Medical Inc
NTUS
+$5.86M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$9.3M
2
AGN
Allergan Inc
AGN
+$8.53M
3
PCRX icon
Pacira BioSciences
PCRX
+$6.34M
4
ITGR icon
Integer Holdings
ITGR
+$3.2M
5
MDAS
MEDASSETS INC COM STK (DE)
MDAS
+$3.16M

Sector Composition

Rank Sector Weight
1 Healthcare 46.46%
2 Technology 2.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLTM
26
DELISTED
SOLTA MED INC (DE)
SLTM
$3.1M 0.82%
1,500,000
-304,391
-17% -$690K
HSTM icon
27
HealthStream
HSTM
$895M
$2.9M 0.77%
+76,423
New +$2.49M
CHE icon
28
Chemed
CHE
$7.03B
$2.65M 0.7%
+37,000
New +$2.63M
CNMD icon
29
CONMED
CNMD
$1.52B
$2.63M 0.7%
+77,393
New +$2.53M
GTIV
30
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
$1.9M 0.5%
157,525
+22,978
+17% +$260K
LAB icon
31
Standard BioTools
LAB
$337M
$965K 0.26%
43,974
-100,428
-70% -$1.97M
NXTM
32
DELISTED
NxStage Medical Inc.
NXTM
$329K 0.09%
+25,000
New +$328K
HAE icon
33
Haemonetics
HAE
$3.94B
– –
-225,000
Closed -$9.3M
AGN
34
DELISTED
Allergan Inc
AGN
– –
-95,000
Closed -$8.53M
1
2

Similar funds

RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
BMCMI
Bryn Mawr Capital Management Inc Bryn Mawr, Pennsylvania $577M AUM 6.5% 1-Year Est. Return
GACM
Green Arrow Capital Management New York $535M AUM 14.21% 1-Year Est. Return
AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return

Tamarack Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Tamarack Capital Management held 34 positions worth $378M, up 112% from $179M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Tamarack Capital Management deployed $168M of net new capital in Q3 2013, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Quest Diagnostics: 375,000 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 70% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $6.34M trimmed.

  • Tamarack Capital Management's largest Q3 2013 buy was Quest Diagnostics: 375,000 shares worth $23.2M.
  • Tamarack Capital Management added most to AUXILIUM PHARAMCEUTICALS INC in Q3 2013, an estimated $9.03M increase.
  • Tamarack Capital Management's biggest Q3 2013 reduction was Pacira BioSciences, cutting an estimated $6.34M.
  • Tamarack Capital Management fully exited Haemonetics in Q3 2013, selling an estimated $9.3M.
  • Tamarack Capital Management's ten largest holdings make up 63% of its $378M portfolio in Q3 2013.
  • Tamarack Capital Management opened 10 new positions and closed 2 in Q3 2013.
  • Tamarack Capital Management's portfolio value rose 112% quarter-over-quarter to $378M.

Based on Tamarack Capital Management's 13F filing for Q3 2013, filed 7 Nov 2013.